WEKO3
アイテム
{"_buckets": {"deposit": "cc44ca00-c8f5-4134-aae1-9c1fa09174b8"}, "_deposit": {"id": "11481", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "11481"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00011481", "sets": ["456", "997"]}, "item_7_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Current Treatment for CML-imatinib: The Tyrosine Kinase Inhibitor Targeting Bcr-Abl Oncoprotein(Molecular Targeted Therapy for Cancer)"}]}, "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2007-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "11", "bibliographicPageEnd": "611", "bibliographicPageStart": "601", "bibliographicVolumeNumber": "121", "bibliographic_titles": [{"bibliographic_title": "新潟医学会雑誌"}, {"bibliographic_title": "新潟医学会雑誌", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The history of treatments for chronic myelogenous leukemia (CML) represents a success story caused by the development of molecular medicine. Imatinib myslate (Glivec), a tyrosine kinase inhibitor targeting the Bcr-Abl oncoprotein, which is associated with the pathogenesis of CML and the most specific marker of CML, has induced not only hematological and cytogenetic remissions but surprising genetic response in the patients of CML in all phases. In this report we present the mechanism of action of imatinib, detection methods of Ph clone used for the evaluation of the effects of imatinib treatment, clinical results of imatinib therapy in Niigata Glivec Study Group, future problems and novel kinase inhibitors nilotinib and dasatinib. Stern cell transplantation remains to be a useful option for getting into the level of complete genetic cure although it has been not generally used as first-line treatment already. Within several years many treatment methods will be available for patients with CML, so standardizes and quantitative methods have to be arranged to clarify the effectiveness of targeting therapy.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "77979", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Narita, Miwako"}]}]}, "item_7_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "新潟医学会"}]}, "item_7_relation_31": {"attribute_name": "異版である", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://ci.nii.ac.jp/naid/110007146174", "subitem_relation_type_select": "URI"}}]}, "item_7_rights_15": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "本文データは学協会の許諾に基づきCiNiiから複製したものである"}]}, "item_7_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "成田, 美和子"}], "nameIdentifiers": [{"nameIdentifier": "77978", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-07"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "110007146174.pdf", "filesize": [{"value": "1.1 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1100000.0, "url": {"label": "110007146174.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/11481/files/110007146174.pdf"}, "version_id": "876c6edd-6d4c-4d12-92d0-9cd1e8149cfb"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "2 慢性骨髄性白血病に対するイマチニブ治療(シンポジウム がんの分子標的治療, 第628回新潟医学会)", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "2 慢性骨髄性白血病に対するイマチニブ治療(シンポジウム がんの分子標的治療, 第628回新潟医学会)"}, {"subitem_title": "2 慢性骨髄性白血病に対するイマチニブ治療(シンポジウム がんの分子標的治療, 第628回新潟医学会)", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["456", "997"], "permalink_uri": "http://hdl.handle.net/10191/32852", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-08-07"}, "publish_date": "2015-08-07", "publish_status": "0", "recid": "11481", "relation": {}, "relation_version_is_last": true, "title": ["2 慢性骨髄性白血病に対するイマチニブ治療(シンポジウム がんの分子標的治療, 第628回新潟医学会)"], "weko_shared_id": null}
2 慢性骨髄性白血病に対するイマチニブ治療(シンポジウム がんの分子標的治療, 第628回新潟医学会)
http://hdl.handle.net/10191/32852
http://hdl.handle.net/10191/3285251970cdb-d6b0-442c-8bc0-de0c06f7dc48
名前 / ファイル | ライセンス | アクション |
---|---|---|
110007146174.pdf (1.1 MB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2015-08-07 | |||||
タイトル | ||||||
タイトル | 2 慢性骨髄性白血病に対するイマチニブ治療(シンポジウム がんの分子標的治療, 第628回新潟医学会) | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | 2 慢性骨髄性白血病に対するイマチニブ治療(シンポジウム がんの分子標的治療, 第628回新潟医学会) | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | departmental bulletin paper | |||||
その他のタイトル | ||||||
その他のタイトル | Current Treatment for CML-imatinib: The Tyrosine Kinase Inhibitor Targeting Bcr-Abl Oncoprotein(Molecular Targeted Therapy for Cancer) | |||||
著者 |
成田, 美和子
× 成田, 美和子 |
|||||
著者別名 | ||||||
識別子 | 77979 | |||||
識別子Scheme | WEKO | |||||
姓名 | Narita, Miwako | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The history of treatments for chronic myelogenous leukemia (CML) represents a success story caused by the development of molecular medicine. Imatinib myslate (Glivec), a tyrosine kinase inhibitor targeting the Bcr-Abl oncoprotein, which is associated with the pathogenesis of CML and the most specific marker of CML, has induced not only hematological and cytogenetic remissions but surprising genetic response in the patients of CML in all phases. In this report we present the mechanism of action of imatinib, detection methods of Ph clone used for the evaluation of the effects of imatinib treatment, clinical results of imatinib therapy in Niigata Glivec Study Group, future problems and novel kinase inhibitors nilotinib and dasatinib. Stern cell transplantation remains to be a useful option for getting into the level of complete genetic cure although it has been not generally used as first-line treatment already. Within several years many treatment methods will be available for patients with CML, so standardizes and quantitative methods have to be arranged to clarify the effectiveness of targeting therapy. | |||||
書誌情報 |
新潟医学会雑誌 en : 新潟医学会雑誌 巻 121, 号 11, p. 601-611, 発行日 2007-11 |
|||||
出版者 | ||||||
出版者 | 新潟医学会 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00290440 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00182415 | |||||
権利 | ||||||
権利情報 | 本文データは学協会の許諾に基づきCiNiiから複製したものである | |||||
著者版フラグ | ||||||
値 | publisher | |||||
異版である | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | URI | |||||
関連識別子 | http://ci.nii.ac.jp/naid/110007146174 |